Addressing therapeutic needs in veterinary health
Anivive Lifesciences Inc Founder, CEO and Chairman Dylan Balsz discussed the company’s mission and how it is working to serve unmet needs in veterinary health.
Anivive Lifesciences Inc Founder, CEO and Chairman Dylan Balsz discussed the veterinary drug development company’s mission and how it is working to serve unmet needs in animal health, during an interview with dvm360®at the Fetch dvm360® Conference in Kansas City, Missouri.
View the video for the full statement. The following is a partial transcript:
Dylan Balsz: Specialty medicine and veterinary pharma can only get so far if the treatments aren’t affordable and broadly available. And, so, with our cancer therapy, we’ve been able to pass that on, and it’s about $2-$5 a day in cost. That’s something that our team has strived really hard for in the last 3 years to make possible and something we’ll continue to do in the future with the rest of our pipeline.
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
Torsemide for canine CHF: Emerging evidence and clinical benefits
June 5th 2025William Rausch, DVM, DACVIM (Cardiology), explains that torsemide offers at least equivalent efficacy to furosemide in canine CHF while significantly reducing short-term mortality/worsening events by approximately 50%.
Read More
